Systemischer Lupus erythematodes

Zusammenfassung Die Betreuung von Patientinnen und Patienten mit SLE stellt nach wie vor eine auch intellektuelle Herausforderung dar. Für die meisten Standardsituationen lassen sich aber klare Grundsätze der Abklärung und Therapie herausarbeiten. Neue Medikamente und internationale erarbeitete Festlegungen der Behandlungsstrategien stellen signifikante Verbesserungen dar und versprechen auch für die kommenden Jahre weiteren Fortschritt.

[1]  B. Rovin,et al.  Predictors of Long‐Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro‐Lupus Nephritis Cohort , 2015, Arthritis & rheumatology.

[2]  B. Diamond,et al.  Commentary: Crossing the Atlantic: The Euro‐Lupus Nephritis Regimen in North America , 2015, Arthritis & rheumatology.

[3]  Andreas Radbruch,et al.  The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus , 2015, Annals of the rheumatic diseases.

[4]  B. Rovin,et al.  Treatment of Lupus Nephritis With Abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study , 2014, Arthritis & rheumatology.

[5]  I. Bruce,et al.  Treat-to-target in systemic lupus erythematosus: recommendations from an international task force , 2014, Annals of the rheumatic diseases.

[6]  R. Fischer-Betz,et al.  Stellungnahme zum Einsatz von Mycophenolat-Mofetil beim systemischen Lupus erythematodes , 2013, Zeitschrift für Rheumatologie.

[7]  J. Levy,et al.  Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids , 2013, Annals of the rheumatic diseases.

[8]  R. Fischer-Betz,et al.  Empfehlungen zum Einsatz von Belimumab beim systemischen Lupus erythematodes , 2013, Zeitschrift für Rheumatologie.

[9]  R. Fischer-Betz.  Rheumatische Erkrankungen in der Schwangerschaft , 2012, Deutsche Medizinische Wochenschrift.

[10]  J. Stockman.  Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis , 2013 .

[11]  R. Fischer-Betz,et al.  Renal Outcome in Patients with Lupus Nephritis Using a Steroid-free Regimen of Monthly Intravenous Cyclophosphamide: A Prospective Observational Study , 2012, The Journal of Rheumatology.

[12]  Caroline Gordon,et al.  Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis , 2012, Annals of the rheumatic diseases.

[13]  R. Fischer-Betz,et al.  Current state of evidence on ‘off-label’ therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland – a consensus report , 2012, Lupus.

[14]  M. Petri,et al.  Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response , 2012, Annals of the rheumatic diseases.

[15]  Gerald McGwin,et al.  Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. , 2012, Arthritis and rheumatism.

[16]  M. Petri,et al.  A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. , 2011, Arthritis and rheumatism.

[17]  M. Petri,et al.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.

[18]  M. Khamashta,et al.  Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies , 2011, Lupus.

[19]  D. D'cruz,et al.  Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial , 2010, Annals of the rheumatic diseases.

[20]  M. Aringer,et al.  Use of methotrexate in patients with systemic lupus erythematosus and primary Sjögren's syndrome. , 2010, Clinical and experimental rheumatology.

[21]  P. Lipsky,et al.  Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. , 2010, Arthritis and rheumatism.

[22]  C. Gordon,et al.  European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies , 2009, Annals of the rheumatic diseases.

[23]  Y. Levy,et al.  The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide , 2009, Annals of the rheumatic diseases.

[24]  C. Gordon,et al.  Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. , 2010, Arthritis and rheumatism.

[25]  C. Gordon,et al.  Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. , 2010, Arthritis and rheumatism.

[26]  I. Nestorov,et al.  An Exploratory Dose-Escalating Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Atacicept in Patients with Systemic Lupus Erythematosus , 2009, Lupus.

[27]  G. Illei,et al.  Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. , 2009, Journal of the American Society of Nephrology : JASN.

[28]  O. Rosen,et al.  Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. , 2009, Blood.

[29]  J. Ioannidis,et al.  EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics , 2007, Annals of the rheumatic diseases.

[30]  L. Pasquier,et al.  Orphanet Journal of Rare Diseases , 2006 .

[31]  Mimi Y. Kim,et al.  Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. , 2005, The New England journal of medicine.

[32]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[33]  M. Khamashta,et al.  Antiphospholipid (Hughes') syndrome , 1997, BMJ.

[34]  A. Steinberg,et al.  Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. , 1991, Arthritis and rheumatism.